- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04648566
Endometrium Immunomodulation by in Utero Administration of Peripheral Blood Mononuclear Cells
Endometrium Immunomodulation Using in Utero Administration of Peripheral Blood Mononuclear Cells
One of the most limiting factors in the field of assisted reproduction is implantation failure. A new approach to increase the chances of success involves the use of cells from the patient's blood, peripheral blood mononuclear cells (PBMC), which once isolated can be cultured for a few days and then inseminated back into the uterine cavity prior to embryo implantation. It has been shown that the immune system plays a major role in the process of embryo implantation. To date, at least three international clinical trials appear to confirm the usefulness of intrauterine administration of PBMC in the setting of repeated implantation failure (RIF) in in vitro fertilization (IVF) (RIF: absence of active pregnancy after ≥ 3 embryo transfers). The clinical pregnancy rate would be doubled or even tripled. This treatment has never been studied in a randomized double-blind clinical trial, in the context of fertilization without RIF or in a classic treatment such as intrauterine insemination (IUI) with the partner sperm.
Our hypothesis is that the creation of an endometrial inflammatory reaction by the administration of PBMC in the uterine cavity allows a better receptivity and consequently a better implantation following an embryo transfer as part of an IVF treatment.
The objective is to evaluate whether intrauterine administration of PBMC improves embryo implantation following assisted reproduction treatment.
The investigators plan to recruit 148 women undergoing IVF and 220 patients undergoing UII with partner sperm to test our hypothesis. The investigators also plan to recruit all RIF patients accepting to participate in the clinical trial. The study will be prospective, randomized and double-blind. The treated group will receive an intrauterine administration of PBMC while the control group will be administered with sperm washing medium only. PBMC will be obtained from a blood sample (maximum 10 ml) a few days before embryo transfer in IVF cases or on the day of sperm insemination in IUI cases. PBMC will then be isolated in the laboratory on a Ficoll gradient in order to eliminate platelets, polynuclear cells and red blood cells. PBMCs will then be stimulated with phytohemagglutinin (PHA) and human chorionic gonadotropin hormone (hCG) for 48 hours. Lymphocyte phenotyping will be assessed before and after cell activation. In addition, the cytokine profile will be established from the supernatant of the stimulated cells. These data will make it possible to establish a link between the pro-versus anti-inflammatory cytokine profile and implantation success versus failure for each patient. Two days after cell seeding, PBMC will be administered into the uterine cavity of the patient. Embryo transfer will be performed in the same way as the standard treatment on day 3 or 5 according to the criteria established by the IVF laboratory and in agreement with the doctor.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Laval, Quebec, Canada, H7S1Z5
- Fertilys inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All infertile patients undergoing in vitro fertilization (IVF) or intrauterine insemination (IUI) with partner's sperm at Fertilys, agreeing to participate in the study and having signed the study participation consent form.
- Study participants must be over 18 years old.
- For the recurrent implantation failure (RIF) group only: Patients described as having RIF, i.e. having had ≥ 3 good quality embryo transfers.
Exclusion Criteria:
- For the randomized IUI and IVF groups only: Patients described as having RIF, i.e. having had ≥ 3 embryo transfers or having had a transfer of more than 3 embryos of good quality.
- Patients requiring a donation of gametes (eggs or spermatozoa).
- Couples in which one or the other has a chromosomal abnormality.
- Patients who are starting an IUI cycle under ovulation testing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: IIU control group
|
Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
|
Active Comparator: IIU PBMC group
|
Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
|
Placebo Comparator: FIV control group
|
Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
|
Active Comparator: FIV PBMC group
|
Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
|
Active Comparator: RIF group
|
Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Biochemical pregnancy rate
Time Frame: Two weeks following embryo transfer or 3 weeks following intrauterine insemination
|
Two weeks following embryo transfer or 3 weeks following intrauterine insemination
|
Clinical pregnancy rate
Time Frame: Six to 8 weeks of gestation
|
Six to 8 weeks of gestation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peripheral blood mononuclear cells populations distribution at Day 0
Time Frame: The day of the patient's ovulation
|
The day of the patient's ovulation
|
Peripheral blood mononuclear cells populations distribution at Day 2
Time Frame: After 48 hours of culture
|
After 48 hours of culture
|
Cytokines expression levels
Time Frame: After 48 hours of culture
|
After 48 hours of culture
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pierre Miron, MD, PhD, Fertilys inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Immunomodulation
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Intrauterine administration of sperm washing medium
-
Boston Medical CenterTerminatedInfertility | Fertility | HIV-1United States
-
University of Missouri-ColumbiaNo longer available
-
FertilysCentre hospitalier de l'Université de Montréal (CHUM)WithdrawnInfertility, FemaleCanada
-
Nadezhda Women's Health HospitalRecruiting
-
Stanford UniversityWithdrawnLiver Transplantation | Renal Insufficiency, Chronic | Acute Kidney Injury | Contrast-induced Nephropathy | Contrast MediaUnited States
-
Nadezhda Women's Health HospitalMedical diagnostic laboratory ImunoVitaRecruitingFemale InfertilityBulgaria
-
Bezmialem Vakif UniversityCompletedPostpartum HemorrhageTurkey
-
St George's, University of LondonTerminatedEndometrial Cancer | Hereditary Non-polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)United Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingOsteoradionecrosis | Malignant Skull Base Neoplasm | Malignant Oral Cavity NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)RecruitingCurrent Every Day Smoker | Cigarette SmokerUnited States